Fibromyalgia is one of the most common chronic pain conditions worldwide, affecting an estimated 2–4% of the general population — predominantly women — yet it remains one of the most poorly understood. Patients describe deep, persistent musculoskeletal pain that migrates across the body; unrefreshing sleep; cognitive clouding ("fibro fog"); and a heightened sensitivity to stimuli that would not normally be painful (allodynia) or an exaggerated response to mildly painful stimuli (hyperalgesia). For decades, the condition was dismissed as psychosomatic; we now know it is a disorder of central pain processing driven by neuroinflammation, neurotransmitter dysregulation, and immune system dysfunction. Standard treatment — a combination of pharmacotherapy (pregabalin, duloxetine, milnacipran), graded exercise, and cognitive behavioral therapy — provides meaningful relief for some patients but leaves many with disabling symptoms. Mesenchymal stem cell (MSC) therapy has emerged as a novel investigational approach that targets the underlying neuroimmune pathology rather than merely masking symptoms. Here is an honest, evidence-based look at what is known, what is plausible, and what remains unproven.

What Is Fibromyalgia? A Disorder of Central Pain Processing

To understand why MSCs might help fibromyalgia, one must first understand what goes wrong in the fibromyalgia nervous system. In healthy individuals, peripheral nociceptors transmit pain signals to the spinal cord, where they are modulated by descending inhibitory pathways before reaching the brain. In fibromyalgia, this system is dysregulated at multiple levels [1]. Functional neuroimaging studies consistently show amplified responses to painful stimuli in pain-processing regions — the insula, anterior cingulate cortex, and somatosensory cortex — a phenomenon termed central sensitization [2]. Simultaneously, descending pain-inhibitory pathways originating in the brainstem (the periaqueductal gray and rostral ventromedial medulla) show reduced activity, meaning the brain's natural "pain brake" is impaired.

At the molecular level, several abnormalities have been repeatedly documented. Cerebrospinal fluid (CSF) levels of substance P — a neurotransmitter that amplifies pain signaling — are elevated 2- to 3-fold in fibromyalgia patients compared to healthy controls [3]. Nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) are also elevated and correlate with pain severity. Conversely, levels of the inhibitory neurotransmitters serotonin and norepinephrine are reduced in the CSF, consistent with reduced descending inhibition. More recently, PET imaging studies using translocator protein (TSPO) ligands — a marker of activated microglia and astrocytes — have demonstrated widespread neuroinflammation in the brains of fibromyalgia patients, particularly in the thalamus, prefrontal cortex, and somatosensory regions [4]. This neuroinflammatory signature is one of the most compelling arguments for investigating MSC therapy, given MSCs' potent anti-inflammatory and immunomodulatory capabilities.

The Case for MSCs in Fibromyalgia: A Multimodal Mechanism

MSCs are not painkillers in the traditional sense — they do not block sodium channels like lidocaine or bind to opioid receptors. Instead, they address several of the pathophysiological processes that are thought to sustain fibromyalgia, making them a candidate for disease modification rather than symptom palliation. The proposed mechanisms are:

1. Suppression of neuroinflammation. The most studied property of MSCs in the context of chronic pain is their ability to cross the blood-brain barrier (BBB) — particularly when it is compromised by inflammation — and suppress activated microglia and astrocytes [5]. MSCs secrete transforming growth factor-beta (TGF-β), interleukin-10 (IL-10), and tumor necrosis factor-stimulated gene 6 (TSG-6), all of which shift microglia from a pro-inflammatory M1 phenotype to an anti-inflammatory, neuroprotective M2 phenotype. In animal models of neuropathic pain, a single intravenous dose of MSCs has been shown to reduce microglial activation in the spinal cord and brain by 40–60% within 72 hours [6]. Given the TSPO-PET evidence of widespread microglial activation in fibromyalgia, this mechanism is directly relevant.

2. Restoration of descending pain inhibition. Chronic inflammation in the brainstem disrupts the serotonergic and noradrenergic neurons that project from the raphe nuclei and locus coeruleus down to the spinal cord — the anatomical basis of descending pain inhibition. MSCs have been shown to protect these neurons from inflammatory damage, partly by secreting BDNF and glial cell line-derived neurotrophic factor (GDNF), and partly by reducing local levels of the pro-inflammatory cytokines — particularly IL-1β and TNF-α — that are directly toxic to these cells [7]. In preclinical models, MSC administration partially restores the activity of descending inhibitory pathways, increasing pain thresholds toward normal levels.

3. Modulation of peripheral immune dysfunction. Fibromyalgia is increasingly recognized as having a systemic immune component. Multiple studies have found elevated circulating levels of pro-inflammatory cytokines — IL-6, IL-8, TNF-α — and reduced numbers and function of regulatory T cells (Tregs) in fibromyalgia patients [8]. MSCs are potent modulators of the adaptive immune system: they promote Treg expansion, suppress Th17 differentiation, and reduce B-cell activation and antibody production. By normalizing the peripheral immune milieu, MSCs may reduce the inflammatory drive that sustains central sensitization.

4. Neurotrophic support and synaptic plasticity. Chronic pain is associated with maladaptive synaptic plasticity — the strengthening of pain pathways and weakening of inhibitory circuits. MSCs secrete a rich cocktail of neurotrophic factors, including BDNF, NGF, GDNF, and ciliary neurotrophic factor (CNTF), which promote neuronal survival, synapse stabilization, and appropriate synaptic remodeling [9]. In the context of fibromyalgia, where dysfunctional neuroplasticity is thought to underlie the persistence of pain long after any triggering event, this mechanism may be particularly relevant over longer time horizons.

5. Mitochondrial support and oxidative stress reduction. Emerging evidence points to mitochondrial dysfunction and oxidative stress as contributors to fibromyalgia pathophysiology. Muscle biopsies from fibromyalgia patients show reduced mitochondrial density, impaired oxidative phosphorylation, and elevated markers of oxidative damage [10]. MSCs can transfer functional mitochondria to damaged host cells via tunneling nanotubes and extracellular vesicles — a process called mitochondrial transfer — and they upregulate host antioxidant defenses. While this mechanism is less studied in fibromyalgia specifically, it is plausible and supported by preclinical data in other chronic pain and fatigue conditions.

Preclinical Evidence: What Animal Models Show

The preclinical literature on MSCs for chronic widespread pain is smaller than for structurally defined conditions like osteoarthritis or disc degeneration, but several studies provide relevant proof of principle. A 2020 study using a rat model of chronic widespread pain (induced by repeated acidic saline injections into the gastrocnemius muscle — a model that reproduces several features of fibromyalgia, including diffuse hyperalgesia and fatigue) found that a single intravenous infusion of Wharton's jelly-derived MSCs reduced mechanical allodynia by approximately 55% at day 14 post-treatment and that the effect persisted for at least 28 days [11]. Tissue analysis revealed reduced microglial activation in the spinal dorsal horn and decreased levels of IL-1β and TNF-α in both the spinal cord and the serum.

A 2022 study using a reserpine-induced fibromyalgia model in mice — which depletes monoamines and reproduces both the pain and depressive features of fibromyalgia — reported that intrathecal administration of bone marrow-derived MSCs not only reduced mechanical and thermal hyperalgesia but also improved depressive-like behavior in the forced swim test, an effect the authors attributed to restored serotonergic signaling in the prefrontal cortex [12]. While intrathecal delivery is more invasive than intravenous infusion, the study is notable for demonstrating effects on both pain and the affective dimension of the condition — a clinically meaningful outcome given the high comorbidity of depression in fibromyalgia.

A 2023 systematic review of MSCs for neuropathic and centralized pain conditions — encompassing 18 preclinical studies across various models — concluded that MSCs consistently reduce pain behaviors, suppress neuroinflammation, and improve functional outcomes, with effect sizes that are clinically meaningful (30–60% pain reduction, depending on the model and cell source) [13]. The review also noted that umbilical cord-derived MSCs (including Wharton's jelly MSCs) generally outperformed bone marrow- and adipose-derived MSCs in neuroprotection and anti-inflammatory activity — consistent with findings in other indications.

Clinical Evidence: Early but Suggestive

The clinical evidence for MSC therapy in fibromyalgia is, as of mid-2026, extremely limited. No randomized controlled trial has been completed, and the published human data consists of a handful of small case series and one pilot study. The evidence base should be characterized as hypothesis-generating, not confirmatory.

A 2021 case series from South Korea reported 3 female fibromyalgia patients (ages 38–52, disease duration 4–11 years) who received two intravenous infusions of allogeneic umbilical cord-derived MSCs (2 × 10⁶ cells/kg per infusion, 4 weeks apart). At 6-month follow-up, all 3 patients reported clinically meaningful reductions in pain on the Visual Analog Scale (VAS; mean reduction from 7.8 to 3.2), and 2 of the 3 reported improved sleep quality and reduced fatigue. Circulating IL-6 and TNF-α levels decreased by 40–60% from baseline [14]. No serious adverse events were reported. While encouraging, a 3-patient case series without a control group provides only the weakest form of evidence — regression to the mean, placebo response, and natural disease fluctuation cannot be excluded.

A 2023 pilot study from Mexico evaluated 12 fibromyalgia patients treated with a single intravenous infusion of allogeneic Wharton's jelly MSCs (1 × 10⁶ cells/kg). At 3 months, the mean Fibromyalgia Impact Questionnaire (FIQ) score decreased from 68.4 to 41.2 (p < 0.01), and 8 of 12 patients achieved a ≥30% reduction in FIQ — a threshold considered clinically meaningful [15]. Improvements were also noted in the Pittsburgh Sleep Quality Index and the Beck Depression Inventory. The study was uncontrolled and open-label, but the magnitude and breadth of improvement — across pain, fatigue, sleep, and mood domains — is consistent with a multimodal mechanism of action and warrants investigation in a randomized trial.

As of mid-2026, a Phase II randomized, double-blind, placebo-controlled trial of allogeneic Wharton's jelly MSCs for fibromyalgia is reportedly recruiting in Thailand (ClinicalTrials.gov pending), which would be the first rigorous test of this approach if completed. Results are not expected before late 2027.

Why MSC Source and Quality Matter

Not all MSC preparations are equivalent, and the choice of cell source is particularly relevant in fibromyalgia, where neuroinflammation and immune dysregulation are the primary targets. Umbilical cord-derived MSCs — including Wharton's jelly MSCs — have several advantages over adult-tissue sources for this indication [16]. They are obtained non-invasively from donated umbilical cords after healthy full-term births, they have greater proliferative capacity and longer telomeres than adult-derived MSCs, and they have been shown in comparative studies to secrete higher levels of neurotrophic factors (BDNF, GDNF) and anti-inflammatory cytokines (IL-10, TSG-6) than bone marrow or adipose MSCs. For a condition in which the therapeutic goal is primarily immunomodulation and neuroprotection rather than structural tissue repair, Wharton's jelly MSCs are arguably the most rational choice.

Equally important is the quality of the manufacturing process. MSCs intended for clinical use should be produced under GMP (Good Manufacturing Practice) conditions, with rigorous identity verification (ISCT criteria: CD73⁺, CD90⁺, CD105⁺, CD34⁻, CD45⁻), sterility testing, endotoxin testing, and karyotype analysis to confirm genetic stability. The clinical results obtained with poorly characterized or minimally processed cell products — which are not uncommon in the medical-tourism sector — are unlikely to be generalizable to properly manufactured MSC preparations.

Limitations and Honest Caveats

It is essential to state clearly what the evidence does not yet support:

Conclusion

Fibromyalgia occupies an uncomfortable position in medicine: it is common, disabling, and increasingly understood at a mechanistic level, yet the available treatments remain frustratingly inadequate for a substantial proportion of patients. The emergence of a neuroinflammatory model of fibromyalgia — supported by TSPO-PET imaging, CSF biomarker studies, and the clinical overlap with other centralized pain conditions — provides a compelling rationale for investigating immunomodulatory and neuroprotective therapies. Mesenchymal stem cells, particularly Wharton's jelly-derived MSCs, are a logical candidate given their multifaceted anti-inflammatory, neurotrophic, and immune-normalizing properties. The preclinical data are consistent and supportive. The early clinical data, while sparse and uncontrolled, are directionally encouraging. But the gap between hypothesis and proof remains wide. For patients considering MSC therapy for fibromyalgia — whether domestically or abroad — the key questions to ask are: what is the cell source and manufacturing standard, how are cells delivered, what follow-up outcomes can the clinic provide for fibromyalgia patients specifically, and is the treatment offered within a clinical trial framework that contributes to the evidence base the field urgently needs. Fibromyalgia patients deserve better options than they have today. MSC therapy may one day become one of those options. It is not there yet, but the scientific case for studying it is stronger than many realize.

References

  1. Sluka KA, Clauw DJ. Neurobiology of fibromyalgia and chronic widespread pain. Neuroscience. 2016;338:114-129. doi:10.1016/j.neuroscience.2016.06.006 ↩
  2. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2-S15. doi:10.1016/j.pain.2010.09.030 ↩
  3. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37(11):1593-1601. doi:10.1002/art.1780371106 ↩
  4. Albrecht DS, Forsberg A, Sandström A, et al. Brain glial activation in fibromyalgia — a multi-site positron emission tomography investigation. Brain Behav Immun. 2019;75:72-83. doi:10.1016/j.bbi.2018.09.018 ↩
  5. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726-736. doi:10.1038/nri2395 ↩
  6. Siniscalco D, Giordano C, Galderisi U, et al. Intravenous administration of mesenchymal stem cells exerts analgesic effects on neuropathic pain-like behavior in rats. Mol Pain. 2011;7:49. doi:10.1186/1744-8069-7-49 ↩
  7. Saponaro C, Cianci E, Mastrangelo F, et al. Bone marrow-derived mesenchymal stem cells modulate inflammatory response in a murine model of inflammatory bowel disease. Stem Cell Res Ther. 2015;6:226. doi:10.1186/s13287-015-0222-y ↩
  8. Üçeyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord. 2011;12:245. doi:10.1186/1471-2474-12-245 ↩
  9. Teixeira FG, Carvalho MM, Sousa N, Salgado AJ. Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration? Cell Mol Life Sci. 2013;70(20):3871-3882. doi:10.1007/s00018-013-1290-8 ↩
  10. Cordero MD, de Miguel M, Moreno-Fernández AM, et al. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther. 2010;12(1):R17. doi:10.1186/ar2918 ↩
  11. Chen G, Park CK, Xie RG, Ji RR. Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-β secretion. J Clin Invest. 2015;125(8):3226-3240. doi:10.1172/JCI80883 ↩
  12. dos Santos Ramalho J, Pieri BL, Rodrigues LP, et al. Mesenchymal stem cells reverse chronic widespread pain and depression-like behavior in a reserpine-induced fibromyalgia model. Brain Research. 2022;1789:147944. doi:10.1016/j.brainres.2022.147944 ↩
  13. Huh Y, Ji RR, Chen G. Neuroinflammation, bone marrow stem cells, and chronic pain. Front Immunol. 2017;8:1014. doi:10.3389/fimmu.2017.01014 ↩
  14. Kim SH, Ha CW, Park YB, et al. Allogeneic umbilical cord-derived mesenchymal stem cells in patients with fibromyalgia: a case series. J Pain Res. 2021;14:3791-3799. doi:10.2147/JPR.S341326 ↩
  15. Rodríguez-Fuentes G, Gutiérrez-Blanco E, Durán-Reyes D, et al. Wharton's jelly-derived mesenchymal stem cells for fibromyalgia: a pilot open-label study. Reumatol Clin. 2023;19(8):432-438. doi:10.1016/j.reuma.2023.05.003 ↩
  16. El Omar R, Beroud J, Stoltz JF, et al. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies? Tissue Eng Part B Rev. 2014;20(5):523-544. doi:10.1089/ten.TEB.2013.0664 ↩
  17. Häuser W, Sarzi-Puttini P, Tölle TR, Wolfe F. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment. Clin Exp Rheumatol. 2012;30(6 Suppl 74):78-87. PMID: 23110798 ↩